- Citius Oncology (NASDAQ:CTOR) expands its distribution network with a new agreement with Cencora for LYMPHIR™.
- The partnership strengthens market readiness and supports near-term revenue generation.
- Cencora will operate as a wholesale distributor, enhancing LYMPHIR's availability nationwide.
Citius Oncology, Inc. (NASDAQ:CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR), has signed a distribution services agreement with Cencora, previously known as AmerisourceBergen. This agreement plays a crucial role in advancing Citius Oncology's commercial strategy for LYMPHIR™ (denileukin diftitox-cxdl), their FDA-approved immunotherapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL).
The collaboration with Cencora significantly enhances Citius Oncology's distribution capabilities by leveraging Cencora's extensive specialty distribution network. This expansion is strategic for increasing LYMPHIR's market penetration, ensuring its broad availability across treatment centers in the United States. The agreement with Cencora complements a previous distribution agreement, further strengthening Citius Oncology's market infrastructure and supporting long-term scalability.
LYMPHIR is specifically designed to treat CTCL, a type of cutaneous non-Hodgkin lymphoma affecting T-cells and causing severe skin lesions. The treatment has shown the ability to deplete immunosuppressive regulatory T lymphocytes and exhibit antitumor activity. With the Cencora agreement, Citius Oncology is well-positioned for its upcoming U.S. market launch, addressing critical supply chain logistics essential for a successful drug launch.
Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharmaceuticals, emphasized the disciplined execution of their market entry strategy, which aims to deliver significant near-term revenue while enhancing long-term shareholder value. The company's robust planning demonstrates a commitment to operational excellence as they prepare for the commercial launch of LYMPHIR.
